<DOC>
	<DOCNO>NCT01046500</DOCNO>
	<brief_summary>Myo-Inositol classified member vitamin B complex . It constituent live cell widespread many food . It involve number biological process , include insulin signal transduction , result modulate insulin sensitivity . One hundred post-menopausal woman 50 60 year old , affected metabolic syndrome ( criterion describe NIH ATP III ) randomize two group : 50 treat myo-inositol 2 g twice per day fifty treat metformin six month . Metformin drug usually use diabetic pre-diabetic condition , metabolic syndrome . The investigator hypothesize administration myo-inositol would improve insulin-receptor activity woman , reduce insulin resistance well metformin . OUTCOME MEASURE : HOMA-IR , blood pressure level , serum triglyceride cholesterol , BMI waist circumference</brief_summary>
	<brief_title>Myo-inositol Versus Metformin Administration Post-menopausal Women With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Postmenopausal outpatient affect metabolic syndrome , whose criterion describe NIH ATP III , 2001 . Postmenopausal outpatients without metabolic syndrome assumption hypocholesterolemic insulin sensitize drug</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>insulin resistance</keyword>
	<keyword>body mass index</keyword>
	<keyword>myo-inositol</keyword>
	<keyword>serum triglyceride cholesterol</keyword>
	<keyword>blood pressure</keyword>
	<keyword>metformin</keyword>
</DOC>